|1.||Coulie, Pierre G: 7 articles (05/2008 - 11/2003)|
|2.||Boon, Thierry: 7 articles (03/2008 - 11/2003)|
|3.||van Baren, Nicolas: 6 articles (03/2008 - 11/2003)|
|4.||Van Pel, Aline: 4 articles (05/2008 - 11/2003)|
|5.||Lucas, Sophie: 3 articles (05/2008 - 11/2003)|
|6.||Godelaine, Danièle: 3 articles (05/2008 - 11/2003)|
|7.||Connerotte, Thierry: 3 articles (05/2008 - 11/2003)|
|8.||Thielemans, Kris: 3 articles (05/2008 - 10/2004)|
|9.||Schuler, Gerold: 3 articles (05/2008 - 07/2002)|
|10.||Lethé, Bernard: 3 articles (03/2008 - 11/2003)|
01/01/2005 - "Clinical manifestations of cancer were shown to develop in HLA-A1, -B8, -B15, -DR3 and -DR5 carriers at early stages. "
05/01/2004 - "IFN-gamma treatment of the GBM tumor cells dramatically increased HLA-A1 expression levels and, consequently, increased CTL recognition of the treated tumor cells. "
11/01/2003 - "We isolated a cytolytic T-lymphocyte clone that lyzed specifically cells pulsed with this MAGE-4 peptide and HLA-A1 tumor cells expressing MAGE-4a, demonstrating that this antigenic peptide is processed efficiently in tumor cells. "
11/01/2003 - "New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells."
11/01/1992 - "Our results open the possibility of immunizing HLA-A1 patients whose tumor expresses MAGE-1 either with the antigenic peptide or with autologous antigen-presenting cells pulsed with the peptide."
|2.||Sarcoidosis (Schaumann Disease)
08/01/1995 - "Findings that were essentially in agreement in both populations were: (1) a positive association of sarcoidosis with HLA-A1, B8, and DR3 markers, and a negative association with HLA-B12 and DR4; (2) a prevalence of HLA-DR3 and DR4 among females and of DR5 among males; (3) a relationship of B13 and B35 with early onset and of A30, B8, DR3, and DR4 with late onset of disease; (4) an association of B27 with sarcoidosis restricted to the lungs; (5) a relationship of A1, B8, B27, and DR3 to roentgenologic stage I and of B12 and DR4 to stage III; and (6) an association of HLA-DR3 with a good outcome. "
06/01/1989 - "The frequencies of HLA-A1, HLA-Bw46, HLA-Cx46, HLA-DRw8, HLA-DRw9, and HLA-DRw52 were significantly increased in sarcoidosis compared to control subjects, but only four patients were positive for HLA-A1. "
|3.||Melanoma (Melanoma, Malignant)
10/24/2008 - "This is in marked contrast with another TCR-like antibody, Hyb3, bound to melanoma peptide MAGE-A1 in association with HLA-A1 MHC class I. Hyb3 assumes a non-canonical orientation over its cognate peptide-MHC and appears to recognize a conformational epitope in which the MHC contribution is dominant. "
02/01/2006 - "We describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide encoded by gene MAGE-A3 and presented by HLA-A1. "
02/01/2006 - "Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1."
07/15/2002 - "First, we affinity matured in vitro a previously selected TCR-like Ab, Fab-G8, which is highly specific for the peptide melanoma-associated Ag-A1 presented by the HLA-A1 molecule. "
12/15/1998 - "To isolate melanoma Ags recognized by T cells, cDNA libraries made from melanoma cell lines were screened with four CTLs derived from tumor infiltrating lymphocytes (TIL) that were able to recognize melanoma cells in a HLA-A1, -A2, or -A3 restricted manner. "
09/01/1993 - "In a study with 46 patients Sengar et al. observed an association of calcifying tendinitis and HLA-A1 in 50% (normal regional frequency: 26.7%). "
09/01/1993 - "Increased frequency of HLA-A1 in calcifying tendinitis? "
03/01/1987 - "Increased frequency of HLA-A1 in calcifying tendinitis."
|1.||HLA-DR3 Antigen (HLA DR3 Antigen)
|5.||HLA-A2 Antigen (HLA A2 Antigen)
|7.||HLA Antigens (Human Leukocyte Antigens)
|8.||Capsid Proteins (Capsid Protein)
|9.||CD58 Antigens (LFA-3)
|10.||Cell Adhesion Molecules